PURPOSE: Level III inferior vena cava tumor thrombectomy for renal cancer is one of the most challenging open urologic oncology surgeries. We present the initial series of completely intracorporeal robotic level III inferior vena cava tumor thrombectomy. MATERIALS AND METHODS: Nine patients underwent robotic level III inferior vena cava thrombectomy and 7 patients underwent level II thrombectomy. The entire operation (high intrahepatic inferior vena cava control, caval exclusion, tumor thrombectomy, inferior vena cava repair, radical nephrectomy, retroperitoneal lymphadenectomy) was performed exclusively robotically. To minimize the chances of intraoperative inferior vena cava thrombus embolization, an "inferior vena cava-first, kidney-last" robotic technique was developed. Data were accrued prospectively. RESULTS: All 16 robotic procedures were successful, without open conversion or mortality. For level III cases (9), median primary kidney (right 6, left 3) cancer size was 8.5 cm (range 5.3 to 10.8) and inferior vena cava thrombus length was 5.7 cm (range 4 to 7). Median operative time was 4.9 hours (range 4.5 to 6.3), estimated blood loss was 375 cc (range 200 to 7,000) and hospital stay was 4.5 days. All surgical margins were negative. There were no intraoperative complications and 1 postoperative complication (Clavien 3b). At a median 7 months of followup (range 1 to 18) all patients are alive. Compared to level II thrombi the level III cohort trended toward greater inferior vena cava thrombus length (3.3 vs 5.7 cm), operative time (4.5 vs 4.9 hours) and blood loss (290 vs 375 cc). CONCLUSIONS: With appropriate patient selection, surgical planning and robotic experience, completely intracorporeal robotic level III inferior vena cava thrombectomy is feasible and can be performed efficiently. Larger experience, longer followup and comparison with open surgery are needed to confirm these initial outcomes.
PURPOSE: Level III inferior vena cava tumor thrombectomy for renal cancer is one of the most challenging open urologic oncology surgeries. We present the initial series of completely intracorporeal robotic level III inferior vena cava tumor thrombectomy. MATERIALS AND METHODS: Nine patients underwent robotic level III inferior vena cava thrombectomy and 7 patients underwent level II thrombectomy. The entire operation (high intrahepatic inferior vena cava control, caval exclusion, tumor thrombectomy, inferior vena cava repair, radical nephrectomy, retroperitoneal lymphadenectomy) was performed exclusively robotically. To minimize the chances of intraoperative inferior vena cava thrombus embolization, an "inferior vena cava-first, kidney-last" robotic technique was developed. Data were accrued prospectively. RESULTS: All 16 robotic procedures were successful, without open conversion or mortality. For level III cases (9), median primary kidney (right 6, left 3) cancer size was 8.5 cm (range 5.3 to 10.8) and inferior vena cava thrombus length was 5.7 cm (range 4 to 7). Median operative time was 4.9 hours (range 4.5 to 6.3), estimated blood loss was 375 cc (range 200 to 7,000) and hospital stay was 4.5 days. All surgical margins were negative. There were no intraoperative complications and 1 postoperative complication (Clavien 3b). At a median 7 months of followup (range 1 to 18) all patients are alive. Compared to level II thrombi the level III cohort trended toward greater inferior vena cava thrombus length (3.3 vs 5.7 cm), operative time (4.5 vs 4.9 hours) and blood loss (290 vs 375 cc). CONCLUSIONS: With appropriate patient selection, surgical planning and robotic experience, completely intracorporeal robotic level III inferior vena cava thrombectomy is feasible and can be performed efficiently. Larger experience, longer followup and comparison with open surgery are needed to confirm these initial outcomes.
Authors: Brian Shuch; Paul L Crispen; Bradley C Leibovich; Jeff C LaRochelle; Frederic Pouliot; Allan J Pantuck; Weiqing Liu; Maxime Crepel; Anne Schuckman; Jerome Rigaud; Oliver Bouchot; Jean-Jacques Patard; Donald Skinner; Arie S Belldegrun; Michael L Blute Journal: BJU Int Date: 2011-03 Impact factor: 5.588
Authors: Paul Sweeney; Christopher G Wood; Louis L Pisters; Joel W Slaton; Ara Vaporciyan; Mark Munsell; Scott Carpenter; Joe Putnam; Stephen G Swisher; Garret Walsh; David Swanson; Colin P N Dinney Journal: Urol Oncol Date: 2003 Sep-Oct Impact factor: 3.498
Authors: Amr F Fergany; Inderbir S Gill; Dana K Schweizer; Jihad H Kaouk; Hazem Abou ElFettouh; Edward E Cherullo; Anoop M Meraney; Gyung Tak Sung Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Mihir M Desai; Inderbir S Gill; Anup P Ramani; Surena F Matin; Jihad H Kaouk; Jose Miguel Campero Journal: J Urol Date: 2003-02 Impact factor: 7.450
Authors: C Alegorides; P Bigot; J Hardwigsen; V Vidal; A Riberi; M Andre; B Gondran-Tellier; M Baboudjian; F Michel; G Karsenty; E Lechevallier; J C Bernhard; R Boissier Journal: Int Urol Nephrol Date: 2020-09-02 Impact factor: 2.370
Authors: Sameer Chopra; Giuseppe Simone; Charles Metcalfe; Andre Luis de Castro Abreu; Jamal Nabhani; Mariaconsiglia Ferriero; Alfredo Maria Bove; Rene Sotelo; Monish Aron; Mihir M Desai; Michele Gallucci; Inderbir S Gill Journal: Eur Urol Date: 2016-09-20 Impact factor: 20.096